Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29407853 | 1.00 | MDM4 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL178741 | 1.00 | MDM4 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL29376536 | 1.00 | MDM4 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL119481 | 1.00 | MDM4 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL25358998 | 0.94 | MDM2 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL31398353 | 0.94 | MDM2 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL31398346 | 0.94 | MDM2 (0.51) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL31689003 | 0.93 | MDM2 (0.50) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL29398655 | 0.92 | TLR2 (0.48) | MDM4TP53TLR2CASP3MDM2 | |
| SCHEMBL14417867 | 0.91 | CASP3 (0.46) | MDM4TP53TLR2CASP3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667483-A1 | HUMAN TRANSFERRIN RECEPTOR-BINDING PEPTIDE | JCR Pharmaceuticals Co., Ltd. (JP) | 2025-12-24 | — | — | EP | disclosed |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| US-20250090699-A1 | FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| WO-2022234852-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090699-A1 | FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | FAP, FIBP, FGF23 | MDM4 2377/4885TP53 273/4885TLR2 3566/4885 |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | ERBB2, EGFR, ERBB3 | MDM4 2510/4885TP53 112/4885TLR2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.